
About Country Condo’s
Country Condo’s is a publicly listed company based in India founded in 1987. Pharmaceutical distribution services are provided by Country Condos in India. The company has 20 employees. Its Indian entity Country Condo's Limited reported revenue of ₹17.49 Cr. Its focus areas include Pharmaceutical Distributors and Diversified. Similar companies include Entero Healthcare, Keimed and Sandor Medicaids; 3 of its 3 listed similar companies have raised funding.
Company details
Country Condos was established in 1987 in India, where pharmaceutical distribution services are managed. Operations are centered on supplying pharmaceutical products to various clients within the sector. The companys activities are conducted primarily in the Indian market, with a focus on efficient distribution networks. Online presence is maintained through the domain countrycondos.co.in. Sector involvement remains limited to pharmaceuticals, supporting regional healthcare needs.
- Headquarters India
- Employees 20
- Stage Public
- SectorsHealthcare
- Website countrycondos.co.in
- Social LinkedIn
- Legal Name Country Condo's Limited
- Market Cap₹48.73 Cr
COUNCODOS · NSE
- Revenue₹17.48 Cr
FY 2025-26 · +4.6% YoY
- EBITDA₹1.01 Cr
Margin 5.8%
- Net Profit₹0.59 Cr
FY 2025-26 · 0.0% YoY
- P/E (TTM)80.4x
P/B 1.9x
- Employee Count20
Associated legal entities of Country Condo’s
Country Condo’s operates through Country Condo's Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Country Condo's Limited Listed CIN L63040TG1987PLC007811 | Active | 25 Sep 1987 | Hyderabad, Telangana | ₹17.5 Cr | 77 | 13 | View details |
Board of directors of Country Condo's Limited (Country Condo’s)
Country Condo's Limited is the primary company behind Country Condo’s. The board of Country Condo's Limited currently have 10 directors; the longest-serving is Krishnakumar Raju Datla, appointed in 1987. 11 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Krishnakumar Raju Datla DIN 00115553 | Director | 25 Sep 1987 | 39 yrs 1 mo | Country Condo's Limited |
| Rajeev Reddy Yedaguri DIN 00115430 | Director | 10 Aug 2009 | 17 yrs 3 mo | Country Condo's Limited |
| Varun Yedaguri Reddy DIN 01905757 | Director | 10 Aug 2009 | 17 yrs 3 mo | Country Condo's Limited |
| Yedaguri Siddharth Reddy DIN 00815456 | Director | 10 Aug 2009 | 17 yrs 3 mo | Country Condo's Limited |
| Manjula Reddy Yedaguri DIN 00115485 | Director | 29 May 2014 | 12 yrs 5 mo | Country Condo's Limited |
| Subramanya Raju Kalidindi DIN 00094663 | Director | 28 Jun 2017 | 9 yrs 4 mo | Country Condo's Limited |
| Korlepara Srirama Chandra Murthy DIN 08197054 | Director | 30 Jun 2020 | 6 yrs 4 mo | Country Condo's Limited |
| Peethala Krupavaram DIN 08197063 | Director | 30 Jun 2020 | 6 yrs 4 mo | Country Condo's Limited |
| Srinivas Pasham DIN 10273557 | Director | 05 Aug 2024 | 2 yrs 3 mo | Country Condo's Limited |
| Rama Lingeswara Swamy Namburi DIN 10720140 | Director | 05 Aug 2024 | 2 yrs 3 mo | Country Condo's Limited |
IPO & Listings of Country Condo’s
Country Condo’s is a publicly listed company on the NSE with ticker symbol COUNCODOS in India, operating in the Finance sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Jan 2009
- Listed onNSE: COUNCODOS
- Listed entityCountry Condo's Limited
- Exchange sectorFinance
- ISININE695B01025
- Share price₹6.38 (+0.79% on the day) · 2026-10-14
- Market capitalisation₹48.3 Cr
- Price to earnings80.7
- EPS (diluted, trailing year)₹0.08
- Volume (last session)25,611
Financials of Country Condo’s
Exchange-reported figures of Country Condo's Limited, the listed company behind Country Condo’s (NSE: COUNCODOS).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 17.48 | 16.71 | 25.32 | 21.10 | 21.93 | 12.44 | 17.89 |
| Revenue growth | +4.6% | -34.0% | +20.0% | -3.8% | +76.3% | -30.5% | - |
| EBITDA | 1.01 | 1.15 | 1.65 | 1.36 | (0.50) | 1.12 | 1.67 |
| EBITDA margin | +5.8% | +6.9% | +6.5% | +6.5% | -2.3% | +9.0% | +9.3% |
| Profit before tax | 0.87 | 0.83 | 1.94 | 1.10 | 3.00 | 0.62 | 0.85 |
| Net profit | 0.59 | 0.59 | 1.03 | 0.82 | (0.53) | 0.45 | 0.62 |
| Net profit margin | +3.4% | +3.5% | +4.1% | +3.9% | -2.4% | +3.6% | +3.5% |
| EPS (₹) | 0.08 | 0.08 | 0.21 | 0.10 | 0.33 | 0.06 | 0.08 |
| Balance sheet | |||||||
| Total assets | 25.69 | 25.15 | 26.45 | 24.55 | 22.19 | 19.86 | 20.15 |
| Net worth | 25.69 | 25.10 | 24.50 | 22.89 | 22.08 | 19.56 | 19.09 |
| Total debt | 0.00 | 0.05 | 1.95 | 1.66 | 0.11 | 0.31 | 1.06 |
| Cash & bank | 0.79 | 0.37 | 3.72 | 4.08 | 4.44 | 2.97 | 4.32 |
| Net working capital | 25.09 | 24.44 | 25.63 | 23.17 | 20.90 | 15.48 | 15.32 |
| Cash flow | |||||||
| Cash from operations | 0.49 | (1.34) | (0.92) | (1.64) | (1.47) | (0.66) | 1.90 |
| Cash from investing | (0.03) | (0.03) | 0.41 | (0.24) | 3.16 | 0.14 | (0.34) |
| Cash from financing | (0.05) | (1.97) | 0.16 | 1.52 | (0.22) | (0.83) | (0.13) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.10 | 3.68 | 4.43 | 5.83 | 3.54 | 2.62 | 4.90 | 4.99 |
| Revenue growth (YoY) | +15.8% | +40.5% | -9.6% | +16.8% | -15.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.04 | 0.03 |
| Total expenses | 3.87 | 3.34 | 4.29 | 5.51 | 3.33 | 2.43 | 4.67 | 4.73 |
| EBITDA | 0.23 | 0.34 | 0.14 | 0.32 | 0.21 | 0.19 | 0.23 | 0.26 |
| EBITDA margin | +5.6% | +9.2% | +3.2% | +5.5% | +5.9% | +7.3% | +4.7% | +5.2% |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| Profit before tax | 0.20 | 0.30 | 0.10 | 0.29 | 0.17 | 0.16 | 0.21 | 0.22 |
| Tax | 0.05 | 0.12 | 0.03 | 0.09 | 0.04 | 0.06 | 0.06 | 0.07 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.10 | 3.68 | 4.43 | 5.83 | 3.54 | 2.62 | 4.90 | 4.99 |
| Revenue growth (YoY) | +15.8% | +40.5% | -9.6% | +16.8% | -15.7% | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.04 | 0.03 |
| Total expenses | 3.87 | 3.34 | 4.29 | 5.51 | 3.33 | 2.43 | 4.67 | 4.73 |
| EBITDA | 0.23 | 0.34 | 0.14 | 0.32 | 0.21 | 0.19 | 0.23 | 0.26 |
| EBITDA margin | +5.6% | +9.2% | +3.2% | +5.5% | +5.9% | +7.3% | +4.7% | +5.2% |
| Depreciation | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 |
| Profit before tax | 0.20 | 0.30 | 0.10 | 0.29 | 0.17 | 0.16 | 0.21 | 0.22 |
| Tax | 0.05 | 0.12 | 0.03 | 0.09 | 0.04 | 0.06 | 0.06 | 0.07 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 17.48 | 16.71 | 25.32 | 21.10 | 21.93 | 12.44 | 17.89 |
| Revenue growth | +4.6% | -34.0% | +20.0% | -3.8% | +76.3% | -30.5% | - |
| Other income | 0.01 | 0.10 | 0.83 | 0.15 | 3.90 | 0.16 | 0.12 |
| Total expenses | 16.47 | 15.56 | 23.67 | 19.74 | 22.43 | 11.32 | 16.22 |
| Employee cost | 0.00 | 4.93 | 5.00 | 4.65 | 4.01 | 3.26 | 2.60 |
| EBITDA | 1.01 | 1.15 | 1.65 | 1.36 | (0.50) | 1.12 | 1.67 |
| EBITDA margin | +5.8% | +6.9% | +6.5% | +6.5% | -2.3% | +9.0% | +9.3% |
| Depreciation | 0.15 | 0.16 | 0.16 | 0.15 | 0.17 | 0.34 | 0.36 |
| Interest | 0.00 | 0.26 | 0.38 | 0.26 | 0.23 | 0.32 | 0.58 |
| Profit before tax | 0.87 | 0.83 | 1.94 | 1.10 | 3.00 | 0.62 | 0.85 |
| Tax | 0.28 | 0.24 | 0.34 | 0.28 | 0.45 | 0.16 | 0.23 |
| Net profit | 0.59 | 0.59 | 1.03 | 0.82 | (0.53) | 0.45 | 0.62 |
| Net profit margin | +3.4% | +3.5% | +4.1% | +3.9% | -2.4% | +3.6% | +3.5% |
| EPS (₹) | 0.08 | 0.08 | 0.21 | 0.10 | 0.33 | 0.06 | 0.08 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.76 | 7.76 | 7.76 | 7.76 | 7.76 | 7.76 | 7.76 |
| Reserves & surplus | 17.93 | 17.34 | 16.74 | 15.13 | 14.32 | 11.80 | 11.33 |
| Shareholders' funds (net worth) | 25.69 | 25.10 | 24.50 | 22.89 | 22.08 | 19.56 | 19.09 |
| Secured loans | 0.00 | 0.05 | 1.95 | 1.66 | 0.11 | 0.18 | 0.33 |
| Unsecured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.73 |
| Total debt | 0.00 | 0.05 | 1.95 | 1.66 | 0.11 | 0.31 | 1.06 |
| Total liabilities | 25.69 | 25.15 | 26.45 | 24.55 | 22.19 | 19.86 | 20.15 |
| Assets | |||||||
| Gross block | 2.61 | 2.58 | 2.55 | 2.96 | 2.72 | 7.08 | 7.30 |
| Net block | 0.54 | 0.65 | 0.78 | 1.35 | 1.26 | 4.59 | 5.06 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 42.94 | 33.76 | 26.51 | 25.26 | 22.98 | 19.72 | 17.22 |
| Sundry debtors | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.79 | 0.37 | 3.72 | 4.08 | 4.44 | 2.97 | 4.32 |
| Loans & advances | 0.66 | 2.35 | 2.61 | 2.45 | 2.42 | 3.54 | 3.90 |
| Total current assets | 44.39 | 36.48 | 32.84 | 31.79 | 29.84 | 26.23 | 25.44 |
| Total current liabilities | 19.30 | 12.04 | 7.21 | 8.62 | 8.94 | 10.75 | 10.12 |
| Net working capital | 25.09 | 24.44 | 25.63 | 23.17 | 20.90 | 15.48 | 15.32 |
| Total assets | 25.69 | 25.15 | 26.45 | 24.55 | 22.19 | 19.86 | 20.15 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.37 | 3.72 | 4.08 | 4.44 | 2.97 | 4.32 | 2.89 |
| Net cash from operating activities | 0.49 | (1.34) | (0.92) | (1.64) | (1.47) | (0.66) | 1.90 |
| Net cash from investing activities | (0.03) | (0.03) | 0.41 | (0.24) | 3.16 | 0.14 | (0.34) |
| Net cash from financing activities | (0.05) | (1.97) | 0.16 | 1.52 | (0.22) | (0.83) | (0.13) |
| Net change in cash | 0.42 | (3.35) | (0.36) | (0.36) | 1.47 | (1.35) | 1.43 |
| Closing cash | 0.79 | 0.37 | 3.72 | 4.08 | 4.44 | 2.97 | 4.32 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +4.6% | -34.0% | +20.0% | -3.8% | +76.3% | -30.5% | - |
| EBITDA growth | -12.2% | -30.3% | +21.3% | +372.0% | -144.6% | -32.9% | - |
| PBT growth | +4.8% | -57.2% | +76.4% | -63.3% | +383.9% | -27.1% | +11.8% |
| Net income growth | 0.0% | -42.7% | +25.6% | +254.7% | -217.8% | -27.4% | - |
| Revenue CAGR (3Y) | -6.1% | -8.7% | +26.7% | +5.7% | +2.6% | -19.5% | -13.0% |
| EBITDA CAGR (3Y) | -9.4% | - | +13.8% | -6.6% | - | -8.0% | +6.1% |
| Profitability & leverage | |||||||
| Net income margin | +3.4% | +3.5% | +6.3% | +3.9% | +11.6% | +3.7% | +3.5% |
| Return on capital employed | - | +4.3% | +6.4% | +5.8% | -2.7% | +4.8% | +7.2% |
| Return on net worth | - | +2.4% | +4.4% | +3.6% | -2.6% | +2.4% | +3.3% |
| Debt / equity | - | 0.04 | 0.08 | 0.04 | 0.01 | 0.04 | 0.06 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.06 |
| Interest cover | 0.00 | 26.26 | 25.50 | 21.49 | -34.33 | 41.03 | 44.27 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 6.51 | 9.19 | 7.43 | 4.48 | 1.73 | 2.51 |
| Inventory turnover | - | 0.55 | 0.98 | 0.87 | 1.03 | 0.67 | 1.13 |
| Debtors turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | 0.08 | 0.08 | 0.21 | 0.10 | 0.33 | 0.06 | 0.08 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 3.23 | 3.16 | 2.95 | 2.85 | 2.52 | 2.46 |
Similar companies to Country Condo’s
Country Condo’s has 3 listed similar companies in our database, 3 of them funded. They include Entero Healthcare, Keimed and Sandor Medicaids.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| enterohealthcare.com | 2018 | Mumbai, India | $59.67M | 817 | India's leading healthcare products distribution platform | |
| keimed.com | 2000 | Hyderabad, India | $16.62M | 588 | Temperature-sensitive medicines are distributed via cold chain logistics by Keimed. | |
| sandor.co.in | 1995 | Hyderabad, India | $8.98M | 161 | Provider of medical equipment, devices, and drugs distribution services |
Detailed similar companies of Country Condos
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Country Condo’s
The website of Country Condo’s (countrycondos.co.in) receives about 8K visits a month.
- Monthly visits8K
▲ 732.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Country Condo’S
Complete news archive for Country Condos
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Country Condo’s
Country Condo’s was founded in 1987.
Country Condo’s is headquartered in India.
Country Condo’s has 20 employees.
The primary company behind Country Condo’s, Country Condo's Limited, reported revenue of ₹17.49 Cr for FY 2026, up 5% year on year.
Country Condos was established in 1987 in India, where pharmaceutical distribution services are managed. Operations are centered on supplying pharmaceutical products to various clients within the sector. The companys activities are conducted primarily in the Indian market, with a focus on efficient distribution networks. Online presence is maintained through the domain countrycondos.co.in. Sector involvement remains limited to pharmaceuticals, supporting regional healthcare needs.
Country Condo’s's top competitors include Entero Healthcare, Keimed and Sandor Medicaids.
Yes, Country Condo’s is publicly traded on NSE under the ticker symbol COUNCODOS.
Country Condo’s operates through Country Condo's Limited.
The legal entities of Country Condo’s currently have 12 directors, including Rajeev Reddy Yedaguri, Manjula Reddy Yedaguri, Krishnakumar Raju Datla and others.
